You are here: Industry Insights > Market News > 29 monoclonal antibody drugs marketed in China

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

29 monoclonal antibody drugs marketed in China

XiaoyaowanNovember 13, 2018

Tag: china , Monoclonal Antibody Drugs

Favorites

China’s monoclonal antibody market is far behind the European and American developed countries no matter in terms of sales scale or product quantity and variety; compared to global market, size of China’s monoclonal antibody market is still small, and is estimated to account for about 1% of global monoclonal antibody market. FDA approved a total of 77 monoclonal antibody drugs by the end of 2017, including 7 monoclonal antibody biosimilars, while the number of monoclonal antibody drugs approved for marketing in China has reached 29, including 19 imported monoclonal antibody drugs and 10 Chinese-produced monoclonal antibody drugs.

Generic name	Trade name	Manufacturer	Marketing time in China
Rituximab	Rituxan	Roche	2000
Trastuzumab	Herceptin	Roche	2002
Basiliximab	Simulect	Novartis	2003
Cetuximab	Erbitux	Merck	2005
Infliximab	Remicade	J & J	2007
Bevacizumab	Avastin	Roche	2010
Adalimumab	Humira	AbbVie	2010
Etanercept	Enbrel	Pfizer	2010
Ranibizumab	Lucentis	Novartis	2011
Tocilizumab	Actemra	Roche	2013
Omalizumab	Xolair	Roche	2017
Ustekinumab	Stelara	J & J	2017
Golimumab	Simponi	J & J	2018
Aflibercept	Eylea	Bayer	2018
Idarucizumab	Praxbind	Boehringer Ingelheim	2018
Nivolumab	Opdivo	BMS	2018
Pembrolizumab	Keytruda	Merck	2018
Evolocumab	Repatha	Amgen	2018
Eculizumab	Soliris	Alexion	2018
Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion	Yisaipu	CP Guojian Pharm	2006
Iodine[131I] tumor necrosis human/mouse chimeric monoclonal antibody	Vivatuxin	MediPharm Biotech	2007
Nimotuzumab	Taixinsheng	Biotech Pharma	2008
Muromomab	/	Wuhan Institute of Biological Products	2010
Anti-human IL-8 monoclonal antibody	Abcream	Asia Space Pharmaceutical [Dalian]	2010
Recombinant human tumor necrosis factor receptor type II-IgG Fc fusion	Qiangke	Celgen Biopharma	2011
Dalizumab	Jiannipai	CP Guojian Pharm	2011
Iodine[131I] metuximab	Likating	Huasun Biotechnology	2011
Conbercept	Langmu	Kanghong Pharmaceutical	2013
Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion	Anbainuo	Hisun Pharmaceutical	2015

Monoclonal antibody drugs in development in China

Amazing Monthly Sales Performance of Opdivo and Keytruda in China

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Amazing Monthly Sales Performance of Opdivo and Keytruda in China

Next:Monoclonal antibody drugs in development in China

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

29 monoclonal antibody drugs marketed in China | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

29 monoclonal antibody drugs marketed in China

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

29 monoclonal antibody drugs marketed in China

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>